2. Academic Validation
  3. Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

  • J Med Chem. 2022 Dec 19. doi: 10.1021/acs.jmedchem.2c01658.
G Leslie Burnett 1,  Yu C Yang 1,  James B Aggen 1,  Jennifer Pitzen 1,  Micah K Gliedt 1,  Chris M Semko 1,  Abby Marquez 1,  James W Evans 1,  Gang Wang 1,  Walter S Won 1,  Aidan C A Tomlinson 1,  Gert Kiss 1,  Christos Tzitzilonis 1,  Arun P Thottumkara 1,  James Cregg 1,  Kevin T Mellem 1,  Jong S Choi 1,  Julie C Lee 1,  Yongyuan Zhao 1,  Bianca J Lee 1,  Justin G Meyerowitz 1,  John E Knox 1,  Jingjing Jiang 1,  Zhican Wang 1,  David Wildes 1,  Zhengping Wang 1,  Mallika Singh 1,  Jacqueline A M Smith 1,  Adrian L Gill 1
Affiliations

Affiliation

  • 1 Revolution Medicines, Incorporated, Redwood City, California 94063, United States.
PMID: 36533617 DOI: 10.1021/acs.jmedchem.2c01658
Abstract

Hyperactivation of mTOR kinase by mutations in the PI3K/mTOR pathway or by crosstalk with other mutant Cancer drivers, such as Ras, is a feature of many tumors. Multiple allosteric inhibitors of mTORC1 and orthosteric dual inhibitors of mTORC1 and mTORC2 have been developed as Anticancer drugs, but their clinical utility has been limited. To address these limitations, we have developed a novel class of "bi-steric inhibitors" that interact with both the orthosteric and the allosteric binding sites in order to deepen the inhibition of mTORC1 while also preserving selectivity for mTORC1 over mTORC2. In this report, we describe the discovery and preclinical profile of the development candidate RMC-5552 and the in vivo preclinical tool compound RMC-6272. We also present evidence that selective inhibition of mTORC1 in combination with covalent inhibition of KRASG12C shows increased antitumor activity in a preclinical model of KRASG12C mutant NSCLC that exhibits resistance to KRASG12C inhibitor monotherapy.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-132168
    98.10%, mTORC1抑制剂
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z